On June 4, 2026, CereVasc, Inc. announced the initial closing of an $85 million Series C financing to advance its eShunt System—a minimally invasive, endovascular approach to treating communicating hydrocephalus, including normal pressure hydrocephalus (NPH). Piper Sandler Merchant Banking led the round, with participation from Johnson & Johnson Innovation – JJDC, Inc., Medtronic, and existing investors Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds. The Charlestown, Massachusetts-based company is clinical-stage; the eShunt System is under development and not commercially available in the United States.
Hydrocephalus is a common neurological condition in which excess cerebrospinal fluid (CSF) accumulates in the brain. Today’s standard of care for many patients is a ventriculo-peritoneal (VP) shunt—an invasive neurosurgical procedure with documented revision rates and outcomes that CereVasc and others have cited as an opportunity for improvement. The eShunt System uses a patented percutaneous transvenous-transdural approach: an endovascularly implantable CSF shunt and delivery components designed to drain fluid from the brain into the venous system without open cranial surgery. Public materials describe a self-expanding nitinol anchor among the delivery components. Any clinical comparison to VP shunts must stay within published trial design and evidence—not sales overclaim.
Proceeds will fund continued clinical and regulatory development, including the ongoing STRIDE pivotal trial (NCT06498960)—a prospective, multi-center, randomized, controlled study comparing the safety and effectiveness of eShunt to VP shunt in NPH patients, intended to support a future FDA premarket approval (PMA) submission. Per the Boston Business Journal, CereVasc is opening a 15,000-square-foot manufacturing facility in Wilmington, Massachusetts, and has cited a regulatory approval target around 2028; timelines can shift with trial readouts, FDA review, and manufacturing readiness. For medical sales professionals, this is a neuro access and neurosurgery-adjacent device story—not cath lab capital, pharma detailing, or a cleared commercial launch today.
Why This Matters for Medical Sales Careers
- PMA pathways typically mean longer evidence and access cycles than many 510(k) predicate devices—field hiring often ramps closer to trial completion and launch prep, not the funding announcement
- Neurosurgery, neurology, and hospital neuro committees are core stakeholders; reps need credibility with procedural workflow, infection risk, and revision economics without practicing medicine
- Strategic participation from Medtronic and Johnson & Johnson Innovation signals category interest from major medtech—not a guarantee of partnership, but a marker that hydrocephalus innovation is on large-cap radar
- Wilmington manufacturing scale-up points to future clinical specialist, operations, and territory roles across Greater Boston—reps who know Massachusetts hospital systems may have an edge at commercialization
- Clinical-stage messaging discipline matters: trial-site support, investigator relationships, and label-scope conversations differ sharply from selling a mature implant line in year five
Hiring and Interview Takeaways
Candidates should prepare examples of selling workflow change in neuro or complex hospital settings: surgeon and advanced practice provider champions, value analysis conversations, infection and revision data handled responsibly, and expansion from pilot sites to broader programs. Interviewers will care how you explain who approves new cerebrospinal fluid management pathways, how you supported clinical evidence discussions, and how you stayed inside regulatory status—not feature lists alone.
Employers building teams around eShunt or similar neuro access platforms should clarify whether roles are clinical trial support, pre-launch market development, or post-PMA territory management—and what year-one targets look like while STRIDE is ongoing. Reps from VP shunt, neuromodulation, or neurovascular backgrounds may transfer relationship skills quickly but need coaching on endovascular delivery mechanics and PMA launch pacing. Boston–Wilmington hiring may cluster clinical specialists and hybrid field roles before full capital-equipment-style territories.